98%
921
2 minutes
20
Background And Hypothesis: Arteriovenous fistula (AVF) is regarded as the most effective vascular access for hemodialysis in patients with end-stage renal disease (ESRD).However, research investigating the relationships between the systemic inflammation response index (SIRI), the triglyceride-glucose index combined with body mass index (TyG-BMI), and the high-sensitivity C-reactive protein to albumin ratio (HRR) with AVF maturation is still limited.
Methods: We included all ESRD patients undergoing first-time AVF creation between March and August 2024 at Haidian Hospital, Beijing (n = 249). To evaluate predictors of AVF maturation failure, we analyzed preoperative clinical/laboratory data and follow-up ultrasound assessments using restricted cubic spline models for dose-response relationships (SIRI, TyG-BMI, HRR). Multivariable Cox models identified independent risk factors, and a predictive nomogram was developed and validated through C-index and calibration plots.
Results: This study included 249 patients (73.5% AVF maturation rate). Restricted cubic spline analysis revealed linear associations between AVF maturation and SIRI (p-overall = 0.047), TyG-BMI (p-overall = 0.039), and HRR (p-overall = 0.026). Multivariable Cox regression identified three independent predictors: SIRI (HR = 1.69, 95%CI:1.45-1.96), TyG-BMI (HR = 2.68, 95%CI:1.62-4.41), and HRR (HR = 1.44, 95%CI:1.28-1.61) (all p < 0.001). The biomarker-based nomogram showed strong predictive accuracy, with calibration curves demonstrating excellent observed-versus-expected agreement.
Conclusion: Non-maturation of AVF was independently associated with three inflammation-based biomarkers, namely SIRI, TyG-BMI, and HRR. High predictive accuracy was demonstrated by the nomogram incorporating these markers, supporting its use for the early identification of high-risk patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304049 | PMC |
http://dx.doi.org/10.1007/s00423-025-03819-0 | DOI Listing |
Clin J Am Soc Nephrol
September 2025
Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL.
For many years, the vascular access guidelines recommended placement of arteriovenous fistulas (AVFs) in preference to arteriovenous grafts (AVGs) because AVFs had superior long-term patency, required fewer interventions to maintain patency, and were associated with lower costs of vascular access management. However, subsequent research has questioned the "Fistula First strategy" (placing an AVF whenever the vascular anatomy is suitable). First, AVF non-maturation is substantial (30-40%), and even higher among women, older patients and those with peripheral vascular disease.
View Article and Find Full Text PDFAnn Vasc Surg
September 2025
Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA. Electronic address:
Objectives: As a two-dimensional modality, venography has limitations in its capacity to measure lumen caliber and to assess stenotic disease accurately. This has implications in the management of end-stage renal-disease (ESRD) patients "no-option" candidates access for arteriovenous fistula (AVF) or graft (AVG) creation secondary to high risk of vascular access failure. The incremental diagnostic and clinical impact of intravascular ultrasound (IVUS) was quantified in this tunneled dialysis catheter dependent ESRD cohort.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Division of Nephrology, Hypertension, and Transplantation, Department of Medicine, University of Florida, Gainesville.
Importance: Predialysis nephrology care is associated with the likelihood of having a mature, usable arteriovenous access for starting hemodialysis (ie, incident vascular access), a key care quality metric for patients with kidney failure. However, the magnitude of this association has not been quantified to date.
Objective: To quantify the attributable association between lack of access to predialysis nephrology care and incident vascular access outcomes among Hispanic patients.
Sci Transl Med
August 2025
Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Worldwide, more than 4 million patients with end-stage kidney disease require hemodialysis through an arteriovenous fistula (AVF). AVFs fail because of venous neointimal hyperplasia (VNH) resulting in venous stenosis formation. A phase 1 randomized trial in patients undergoing upper extremity AVF placement was performed to evaluate the safety and efficacy of autologous adipose-derived mesenchymal stem cells (MSCs) in improving AVF function.
View Article and Find Full Text PDFVasa
August 2025
2nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, Greece.
We investigated the safety and efficacy of antiplatelet therapy in preventing native arteriovenous fistula (AVF) dysfunction. A systematic review was conducted in accordance with the PRISMA 2020 guidelines. Randomized controlled trials (RCTs) evaluating the effects of antiplatelet therapy following native AVF creation were eligible for inclusion.
View Article and Find Full Text PDF